Ignyta, an oncology focused biopharma company, has acquired worldwide rights and assets to four of Teva Pharmaceutical’s targeted oncology development programs in exchange for 1.5 million shares (6%) of Ignyta’s stock. Ignyta has entered into stock purchase agreements with Teva and selected additional healthcare investors, with the offering valued at approximately $41.6 million.   “Teva has committed to finding novel ways for the ongoing development of early clinical stage and pre-clinical oncol...